Free Trial

10 Best Penny Stocks to Buy Now - 5 of 10

 
 

Invivyd (NASDAQ:IVVD)

Number of Upgrades from Top-Ranked Analysts
4 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.3
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$11.33 (1,431.5% Upside)

About Invivyd

Invivyd logoInvivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/30/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
10/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
4/5/2024GuggenheimUpgradeNeutral ➝ Buy$9.00
3/26/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$4.00 ➝ $10.00
3/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
1/18/2024HC WainwrightBoost Price TargetBuy ➝ Buy$5.00 ➝ $15.00
 

2024 Election Year Stocks: Uncover Hidden Gems! (Ad)

In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.

Secure your copy now by clicking this link.